Latest / Bloomberg Intelligence
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker
Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.
Bloomberg Intelligence hosted by Paul Sweeney and Scarlet Fu
-Sam Fazeli, Bloomberg Intelligence, Director of Research: Healthcare, Defence, Industrials & Auto, discusses the latest in the biotech sector. Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in psychedelic medicine.
Separately, Merck & Co. won US regulatory approval of a pill called Lipfendra to reduce LDL cholesterol.
-Matt Henriksson, Bloomberg Intelligence Senior Equity Analyst…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.